Susquehanna Portfolio Strategies’s Vertex Pharmaceuticals VRTX Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$45.2M	Buy	90,928 +61,739	+212%	+$27.4M	0.72%	28
2026 Q1	$13M	Hold	29,189	–	–	0.19%	140
2025 Q4	$13.2M	Buy	29,189 +2,405	+9%	+$1.04M	0.2%	135
2025 Q3	$10.5M	Buy	+26,784	New	+$11.2M	0.17%	174
2024 Q4	–	Sell	-602	Closed	-$280K	–	323
2024 Q3	$280K	Sell	602 -604	-50%	-$290K	0.02%	291
2024 Q2	$565K	Sell	1,206 -9,453	-89%	-$4.1M	0.02%	352
2024 Q1	$4.46M	Sell	10,659 -82,519	-89%	-$34.9M	0.1%	231
2023 Q4	$37.9M	Buy	+93,178	New	+$34.4M	0.67%	21

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Susquehanna Portfolio Strategies's VRTX Position: Q2 2026 in Review

Susquehanna Portfolio Strategies increased its Vertex Pharmaceuticals (VRTX) stake by 212% in Q2 2026, buying an estimated $27.4M and bringing the position to 90,928 shares worth $45.2M. The position accounts for 0.72% of the portfolio, ranked #28.

Susquehanna Portfolio Strategies first reported a position in VRTX in Q4 2023 and has held it in 8 quarters since. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Susquehanna Portfolio Strategies held 90,928 shares of Vertex Pharmaceuticals worth $45.2M as of Q2 2026.
Susquehanna Portfolio Strategies bought 61,739 Vertex Pharmaceuticals shares in Q2 2026, an estimated $27.4M.
Vertex Pharmaceuticals made up 0.72% of Susquehanna Portfolio Strategies's portfolio in Q2 2026, its #28 holding.
Susquehanna Portfolio Strategies first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 8 quarters since.
1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.